<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05036525</url>
  </required_header>
  <id_info>
    <org_study_id>HAN2013001-CT02</org_study_id>
    <nct_id>NCT05036525</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of a Hyaluronic Acid Gel in Adhesion Prevention After Open Thyroidectomy.</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of a High Molecular Weight Native Hyaluronic Acid Gel (HANBIO BarriGel) in Adhesion Prevention After Open Thyroidectomy: a Prospective, Randomized Controlled, Single Blind Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HAN Biomedical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HAN Biomedical Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the safety and efficacy of HANBIO BarriGel to prevent&#xD;
      thyroidectomy postoperative adhesions&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the efficacy of HANBIO BarriGel in the prevention&#xD;
      of postoperative adhesion for patients who will undergo open thyroidectomy. The dysphagia and&#xD;
      adhesion severity will be assessed at specific visits pre and/or post-operation for both&#xD;
      treatment group and control group. The post-operative condition, and the adverse event&#xD;
      information will be collected for evaluation of tolerability and safety of the product.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dysphagia Handicap Index (DHI)</measure>
    <time_frame>Preoperative 6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Adhesion</condition>
  <condition>Thyroid Diseases</condition>
  <arm_group>
    <arm_group_label>use HANBIO BarriGel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No anti-adhesive product</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HANBIO BarriGel</intervention_name>
    <description>an anti-adhesive product</description>
    <arm_group_label>use HANBIO BarriGel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female between 20 and 70 years of age.&#xD;
&#xD;
          -  Patients diagnosed with benign goiter or thyroid cancer that will undergo open&#xD;
             thyroidectomy (either unilateral or bilateral total thyroidectomy with or without&#xD;
             central lymph node dissection).&#xD;
&#xD;
          -  Na√Øve patients to thyroid surgery.&#xD;
&#xD;
          -  Subjects are willing to comply with all aspects of the study and have signed informed&#xD;
             consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating female patients.&#xD;
&#xD;
          -  Presence of severe and uncontrolled illness such as stroke, hypertension, diabetes,&#xD;
             chronic renal failure, coagulopathy, drug abuse.&#xD;
&#xD;
          -  Patients with previous neck radiotherapy within 1 year.&#xD;
&#xD;
          -  Concurrent diseases/conditions which will be unable to evaluate the outcomes.&#xD;
&#xD;
          -  Patients receiving any adhesion prevention adjuvant.&#xD;
&#xD;
          -  Previous history of Keloid or hypertrophic scar.&#xD;
&#xD;
          -  Anticoagulant used within a week from surgery.&#xD;
&#xD;
          -  Subjects are hypersensitive to sodium hyaluronate.&#xD;
&#xD;
          -  Participate in another clinical trial within 1 month.&#xD;
&#xD;
          -  Patients presence of surgical site infection.&#xD;
&#xD;
          -  Patients are with abnormal clinical test (appendix 1) result within one month or ECOG&#xD;
             performance status (appendix 2) score ranged from 3-4.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wen Lin Wu</last_name>
    <phone>886-2-26971328</phone>
    <email>hanbio008@hanbiomedical.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Tissue Adhesions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

